AKT is a therapeutic target in myeloproliferative neoplasms

AKT is a therapeutic target in myeloproliferative neoplasms

The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN an...

Full description

Bibliographic Details
Main Authors: Khan, Irum, Huang, Zan, Wen, Qiang, Stankiewicz, Monika J., Gilles, Laure, Goldenson, Benjamin, Schultz, Rachael, Diebold, Lauren, Gurbuxani, Sandeep, Finke, Christy M., Lasho, Terra L., Koppikar, Priya, Pardanani, Animesh, Stein, Brady, Altman, Jessica K., Levine, Ross L., Tefferi, Ayalew, Crispino, John D.
Format: Online
Language:English
Published: 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023863/

Similar Items

Similar Items